Journal of Clinical Oncology, Vol 8, 715-720, Copyright © 1990 by American Society of Clinical Oncology

ARTICLES

Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin

DM Gershenson, M Morris, A Cangir, JJ Kavanagh, CA Stringer, CL Edwards, EG Silva and JT Wharton
Department of Gynecology, University of Texas MD Anderson Cancer Center, Houston 77030.

Since 1984, we have treated 26 patients with malignant ovarian germ cell tumors with a combination of bleomycin, etoposide (VP-16), and cisplatin (BEP) at The University of Texas MD Anderson Cancer Center (UTMDACC). The median age of the patients was 19 years (range, 8 to 32). All patients underwent initial surgery (unilateral salpingo- oophorectomy in 14, unilateral salpingo-oophorectomy plus abdominal hysterectomy in one, and bilateral salpingo-oophorectomy with or without hysterectomy in 11 patients). Twenty patients had no residual disease, three had less than or equal to 2 cm (one each, dysgerminoma, mixed, and immature teratoma), and three had more than 2 cm lesions (two dysgerminomas, one endodermal sinus tumor). Fourteen patients had pure dysgerminoma (five, stage I; one, stage II; six, stage III; and two, recurrent), and 12 had nondysgerminomatous tumors (five, stage I; two, stage II; three, stage III; and two, recurrent). All four patients with clinically measurable disease had a complete response. All four patients who underwent second-look laparotomy had negative findings. Twenty-five patients (96%) remain in sustained remission 10.4 to 54.4 months from the start of chemotherapy. One patient died of progressive disease 14 months after beginning chemotherapy. We conclude that the BEP regimen has excellent activity and acceptable toxicity in patients with malignant ovarian germ cell tumors.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. Matei, A. M. Miller, P. Monahan, D. Gershenson, Q. Zhao, D. Cella, V. L. Champion, and S. D. Williams Chronic Physical Effects and Health Care Utilization in Long-Term Ovarian Germ Cell Tumor Survivors: A Gynecologic Oncology Group Study J. Clin. Oncol., September 1, 2009; 27(25): 4142 - 4149. [Abstract] [Full Text] [PDF]

				M. Cvancarova, S. O. Samuelsen, H. Magelssen, and S. D. Fossa Reproduction Rates After Cancer Treatment: Experience From the Norwegian Radium Hospital J. Clin. Oncol., January 20, 2009; 27(3): 334 - 343. [Abstract] [Full Text] [PDF]

				T. de La Motte Rouge, P. Pautier, P. Duvillard, A. Rey, P. Morice, C. Haie-Meder, P. Kerbrat, S. Culine, F. Troalen, and C. Lhomme Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor Ann. Onc., August 1, 2008; 19(8): 1435 - 1441. [Abstract] [Full Text] [PDF]

				D. M. Gershenson Management of Ovarian Germ Cell Tumors J. Clin. Oncol., July 10, 2007; 25(20): 2938 - 2943. [Abstract] [Full Text] [PDF]

				D. M. Gershenson, A. M. Miller, V. L. Champion, P. O. Monahan, Q. Zhao, D. Cella, and S. D. Williams Reproductive and Sexual Function After Platinum-Based Chemotherapy in Long-Term Ovarian Germ Cell Tumor Survivors: A Gynecologic Oncology Group Study J. Clin. Oncol., July 1, 2007; 25(19): 2792 - 2797. [Abstract] [Full Text] [PDF]

				M. Brewer, D. M. Gershenson, C. E. Herzog, M. F. Mitchell, E. G. Silva, and J. T. Wharton Outcome and Reproductive Function After Chemotherapy for Ovarian Dysgerminoma J. Clin. Oncol., September 1, 1999; 17(9): 2670 - 2670. [Abstract] [Full Text] [PDF]

				N. M. Marina, B. Cushing, R. Giller, L. Cohen, S. J. Lauer, A. Ablin, R. Weetman, J. Cullen, P. Rogers, C. Vinocur, et al. Complete Surgical Excision Is Effective Treatment for Children With Immature Teratomas With or Without Malignant Elements: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study J. Clin. Oncol., July 1, 1999; 17(7): 2137 - 2137. [Abstract] [Full Text] [PDF]